Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2023

Nov 15, 2023

SELL
$0.4 - $0.63 $19,330 - $30,446
-48,327 Reduced 59.08%
33,476 $14,000
Q2 2023

Aug 14, 2023

SELL
$0.51 - $0.67 $5,768 - $7,578
-11,311 Reduced 12.15%
81,803 $44,000
Q1 2023

May 15, 2023

BUY
$0.6 - $0.91 $5,440 - $8,251
9,068 Added 10.79%
93,114 $61,000
Q4 2022

Feb 14, 2023

SELL
$0.48 - $5.33 $68,689 - $762,738
-143,103 Reduced 63.0%
84,046 $52,000
Q3 2022

Nov 14, 2022

BUY
$4.65 - $7.37 $406,754 - $644,683
87,474 Added 62.63%
227,149 $1.1 Million
Q2 2022

Oct 27, 2022

BUY
$4.21 - $11.15 $454,709 - $1.2 Million
108,007 Added 341.06%
139,675 $645,000
Q2 2022

Aug 15, 2022

BUY
$4.21 - $11.15 $454,709 - $1.2 Million
108,007 Added 341.06%
139,675 $645,000
Q1 2022

Oct 27, 2022

SELL
$8.48 - $18.1 $915,899 - $1.95 Million
-108,007 Reduced 77.33%
31,668 $340,000
Q1 2022

May 13, 2022

SELL
$8.48 - $18.1 $106,983 - $228,349
-12,616 Reduced 28.49%
31,668 $340,000
Q4 2021

Feb 14, 2022

BUY
$15.37 - $22.5 $568,044 - $831,555
36,958 Added 504.48%
44,284 $757,000
Q3 2021

Nov 15, 2021

BUY
$15.05 - $23.28 $110,256 - $170,549
7,326 New
7,326 $131,000

Others Institutions Holding TIL

About Instil Bio, Inc.


  • Ticker TIL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 129,694,000
  • Market Cap $2.67B
  • Description
  • Instil Bio, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of patients with cancer. The company develops cell therapy of autologous tumor infiltrating lymphocyte (TIL). Its TIL product candidates in pipeline include ITIL-168 for indications, such as melanoma, cutaneous squamous cell carcinoma, non-small ce...
More about TIL
Track This Portfolio

Track Morgan Stanley Portfolio

Follow Morgan Stanley and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

News

Stay updated on Morgan Stanley with notifications on news.